SCHEMBL30905706

SCHEMBL30905706

N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)NCC(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 8/20 0.43
▸ ACE2 Q9BYF1 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ PTGS1 P23219 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ F2 P00734 1/20 0.43
▸ REN P00797 1/20 0.43
▸ LTA4H P09960 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ PEPD P12955 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ HTR2A P28223 1/20 0.43
▸ PTGS2 P35354 1/20 0.43
▸ HRH1 P35367 1/20 0.43
▸ THPO P40225 1/20 0.43
▸ PMP22 Q01453 1/20 0.43
▸ CYP2C19 P33261 1/20 0.38
▸ GSTK1 Q9Y2Q3 1/20 0.37
▸ DPP4 P27487 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29464996 0.87 ACE (0.48) ACEACE2LMNAHSD17B10PTGS1
SCHEMBL29379676 0.86 ACE (0.54) ACEACE2LMNAHSD17B10PTGS1
SCHEMBL30066883 0.85 ACE (0.55) ACEACE2
SCHEMBL30905703 0.84 ACE (0.44) ACEACE2LMNAHSD17B10PTGS1
SCHEMBL30186409 0.84 ACE (0.46) ACEACE2LMNAHSD17B10PTGS1
SCHEMBL30605149 0.84 ACE (0.50) ACEACE2LMNAHSD17B10PTGS1
SCHEMBL30905695 0.83 ACE (0.48) ACEACE2LMNAHSD17B10PTGS1
SCHEMBL29411125 0.83 ACE (0.43) ACEACE2LMNAHSD17B10PTGS1
SCHEMBL31257058 0.82 PLK1 (0.40) ACEACE2DPP4
SCHEMBL30463402 0.82 ACE (0.50) ACEACE2LMNAHSD17B10PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206802-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-06-26 — — US disclosed
US-20240117006-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2024-04-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240117006-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF ITGA2B, ITGB1, ITGA1 ACE 3963/4885ACE2 3654/4885LMNA 2506/4885
US-20250206802-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF ITGA2B, ITGB1, ITGA1 ACE 3963/4885ACE2 3654/4885LMNA 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback